Stratified medicine approaches for the treatment of musculoskeletal disorders

Lynne J Hocking, Fernando Rivadeneira

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Stratified medicine approaches for the treatment of musculoskeletal disorders offer opportunities to effectively target interventions to those individuals who will gain most benefit from them and minimise adverse side effects. Such approaches have been the 'holy grail' of a variety of research fields spanning epidemiological, (epi)genetic, transcriptomic, proteomic and imaging biomarkers that predict disease diagnosis, prognosis or response to treatment. In this review, we highlight the successes and opportunities for stratified medicine approaches across a range of musculoskeletal disorders, with a focus on genetic risk factors, since these are the most stable across the lifetime of each individual.

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalCurrent Opinion in Pharmacology
Volume16
Early online date31 May 2014
DOIs
Publication statusPublished - Jun 2014

Fingerprint

Medicine
Proteomics
Biomarkers
Research

Cite this

Stratified medicine approaches for the treatment of musculoskeletal disorders. / Hocking, Lynne J; Rivadeneira, Fernando.

In: Current Opinion in Pharmacology, Vol. 16, 06.2014, p. 127-132.

Research output: Contribution to journalArticle

Hocking, Lynne J ; Rivadeneira, Fernando. / Stratified medicine approaches for the treatment of musculoskeletal disorders. In: Current Opinion in Pharmacology. 2014 ; Vol. 16. pp. 127-132.
@article{cf255b0b66ea4c249e80da7dbfffcf50,
title = "Stratified medicine approaches for the treatment of musculoskeletal disorders",
abstract = "Stratified medicine approaches for the treatment of musculoskeletal disorders offer opportunities to effectively target interventions to those individuals who will gain most benefit from them and minimise adverse side effects. Such approaches have been the 'holy grail' of a variety of research fields spanning epidemiological, (epi)genetic, transcriptomic, proteomic and imaging biomarkers that predict disease diagnosis, prognosis or response to treatment. In this review, we highlight the successes and opportunities for stratified medicine approaches across a range of musculoskeletal disorders, with a focus on genetic risk factors, since these are the most stable across the lifetime of each individual.",
author = "Hocking, {Lynne J} and Fernando Rivadeneira",
note = "Copyright {\circledC} 2014 Elsevier Ltd. All rights reserved. Acknowledgements The work of LJH in this area is funded by Arthritis Research UK and the Paget's Association UK. FR is funded by the Netherlands Scientific Organization ProjectNWO-ZonMW VIDI 016.136.367.",
year = "2014",
month = "6",
doi = "10.1016/j.coph.2014.05.003",
language = "English",
volume = "16",
pages = "127--132",
journal = "Current Opinion in Pharmacology",
issn = "1471-4892",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Stratified medicine approaches for the treatment of musculoskeletal disorders

AU - Hocking, Lynne J

AU - Rivadeneira, Fernando

N1 - Copyright © 2014 Elsevier Ltd. All rights reserved. Acknowledgements The work of LJH in this area is funded by Arthritis Research UK and the Paget's Association UK. FR is funded by the Netherlands Scientific Organization ProjectNWO-ZonMW VIDI 016.136.367.

PY - 2014/6

Y1 - 2014/6

N2 - Stratified medicine approaches for the treatment of musculoskeletal disorders offer opportunities to effectively target interventions to those individuals who will gain most benefit from them and minimise adverse side effects. Such approaches have been the 'holy grail' of a variety of research fields spanning epidemiological, (epi)genetic, transcriptomic, proteomic and imaging biomarkers that predict disease diagnosis, prognosis or response to treatment. In this review, we highlight the successes and opportunities for stratified medicine approaches across a range of musculoskeletal disorders, with a focus on genetic risk factors, since these are the most stable across the lifetime of each individual.

AB - Stratified medicine approaches for the treatment of musculoskeletal disorders offer opportunities to effectively target interventions to those individuals who will gain most benefit from them and minimise adverse side effects. Such approaches have been the 'holy grail' of a variety of research fields spanning epidemiological, (epi)genetic, transcriptomic, proteomic and imaging biomarkers that predict disease diagnosis, prognosis or response to treatment. In this review, we highlight the successes and opportunities for stratified medicine approaches across a range of musculoskeletal disorders, with a focus on genetic risk factors, since these are the most stable across the lifetime of each individual.

U2 - 10.1016/j.coph.2014.05.003

DO - 10.1016/j.coph.2014.05.003

M3 - Article

C2 - 24880767

VL - 16

SP - 127

EP - 132

JO - Current Opinion in Pharmacology

JF - Current Opinion in Pharmacology

SN - 1471-4892

ER -